Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca, Merck form oncology pact
by Michael McCoy
July 31, 2017
| A version of this story appeared in
Volume 95, Issue 31
AstraZeneca and Merck & Co. will work together to broaden the application of AstraZeneca’s Lynparza, a small-molecule PARP inhibitor approved in 2014 to treat BRCA-mutated ovarian cancer. The two firms will develop Lynparza for other cancers both on its own and in combination with other drugs, including AstraZeneca’s Imfinzi and Merck’s Keytruda, immuno-oncology antibodies known as checkpoint inhibitors. Merck will pay AstraZeneca $1.6 billion up front and up to $6.9 billion more in milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter